180 related articles for article (PubMed ID: 8314382)
1. Heterogeneity of chemosensitivity in human breast carcinoma: use of an adenosine triphosphate (ATP) chemiluminescence assay.
Hunter EM; Sutherland LA; Cree IA; Dewar JA; Preece PE; Wood RA; Linder D; Andreotti PE
Eur J Surg Oncol; 1993 Jun; 19(3):242-9. PubMed ID: 8314382
[TBL] [Abstract][Full Text] [Related]
2. [-Chemosensitivity testing in gynecologic oncology. Experiences with an ATP bioluminescence assay-].
Kurbacher CM; Mallmann P; Kurbacher JA; Hübner H; Krebs D
Geburtshilfe Frauenheilkd; 1996 Feb; 56(2):70-8. PubMed ID: 8647362
[TBL] [Abstract][Full Text] [Related]
3. In vitro chemosensitivity in breast cancer using ATP-tumor chemosensitivity assay.
Qi CJ; Ning YL; Zhu YL; Min HY; Ye H; Qian KQ
Arch Pharm Res; 2009 Dec; 32(12):1737-42. PubMed ID: 20162402
[TBL] [Abstract][Full Text] [Related]
4. [Correlation between ATP bioluminescence tumor chemosensitivity assay and clinical response in ovarian cancer].
Tian HM; Shi XY; Fu J; Chao DY; Zhang K; Wu LY; Wang JW; Zhang W
Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):296-8. PubMed ID: 15996325
[TBL] [Abstract][Full Text] [Related]
5. Anticancer chemosensitivity profiles of human breast cancer cells assessed by in vitro DNA synthesis inhibition assay.
Nio Y; Tamura K; Kan N; Inamoto T; Ohgaki K; Kodama H
Anticancer Res; 2000; 20(2B):1237-44. PubMed ID: 10810427
[TBL] [Abstract][Full Text] [Related]
6. Chemosensitivity testing using microplate adenosine triphosphate-based luminescence measurements.
Kurbacher CM; Cree IA
Methods Mol Med; 2005; 110():101-20. PubMed ID: 15901931
[TBL] [Abstract][Full Text] [Related]
7. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma.
Andreotti PE; Cree IA; Kurbacher CM; Hartmann DM; Linder D; Harel G; Gleiberman I; Caruso PA; Ricks SH; Untch M
Cancer Res; 1995 Nov; 55(22):5276-82. PubMed ID: 7585588
[TBL] [Abstract][Full Text] [Related]
8. Predictive value of the ATP chemosensitivity assay in epithelial ovarian cancer.
O'Meara AT; Sevin BU
Gynecol Oncol; 2001 Nov; 83(2):334-42. PubMed ID: 11606094
[TBL] [Abstract][Full Text] [Related]
9. [Value of the adenosine triphosphate chemosensitivity assay for pre-therapeutic determination of the chemosensitivity of breast cancer cells in cell culture].
Köchli OR; Sevin BU; Schär G; Haller U
Geburtshilfe Frauenheilkd; 1995 Jan; 55(1):7-16. PubMed ID: 7705600
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemotherapy for breast cancer determined by chemosensitivity assay achieves better tumor response.
Lau GI; Loo WT; Chow LW
Biomed Pharmacother; 2007 Oct; 61(9):562-5. PubMed ID: 17913448
[TBL] [Abstract][Full Text] [Related]
11. Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma.
Sharma S; Neale MH; Di Nicolantonio F; Knight LA; Whitehouse PA; Mercer SJ; Higgins BR; Lamont A; Osborne R; Hindley AC; Kurbacher CM; Cree IA
BMC Cancer; 2003 Jul; 3():19. PubMed ID: 12841853
[TBL] [Abstract][Full Text] [Related]
12. Adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided platinum-based 2-drug chemotherapy for unresectable nonsmall-cell lung cancer.
Moon YW; Choi SH; Kim YT; Sohn JH; Chang J; Kim SK; Park MS; Chung KY; Lee HJ; Kim JH
Cancer; 2007 May; 109(9):1829-35. PubMed ID: 17366594
[TBL] [Abstract][Full Text] [Related]
13. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer.
Konecny G; Crohns C; Pegram M; Felber M; Lude S; Kurbacher C; Cree IA; Hepp H; Untch M
Gynecol Oncol; 2000 May; 77(2):258-63. PubMed ID: 10785475
[TBL] [Abstract][Full Text] [Related]
14. [Locally advanced non inflammatory breast cancer treated by combined chemotherapy and preoperative irradiation: updated results in a series of 120 patients].
Lerouge D; Touboul E; Lefranc JP; Genestie C; Moureau-Zabotto L; Blondon J
Cancer Radiother; 2004 Jun; 8(3):155-67. PubMed ID: 15217583
[TBL] [Abstract][Full Text] [Related]
15. Potential use of the adenosine triphosphate cell viability assay in endometrial cancer.
Tam KF; Ng TY; Tsang PC; Li CF; Ngan HY
J Soc Gynecol Investig; 2006 Oct; 13(7):518-22. PubMed ID: 16979354
[TBL] [Abstract][Full Text] [Related]
16. A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer.
Cree IA; Kurbacher CM; Lamont A; Hindley AC; Love S;
Anticancer Drugs; 2007 Oct; 18(9):1093-101. PubMed ID: 17704660
[TBL] [Abstract][Full Text] [Related]
17. Acquisition of multidrug resistance in recurrent breast cancer demonstrated by the histoculture drug response assay.
Tanino H; Oura S; Hoffman RM; Kubota T; Furukawa T; Arimoto J; Yoshimasu T; Hirai I; Bessho T; Suzuma T; Sakurai T; Naito Y
Anticancer Res; 2001; 21(6A):4083-6. PubMed ID: 11911296
[TBL] [Abstract][Full Text] [Related]
18. [Comparison of the cytostatic effect of epirubicin and mitoxantrone on native breast carcinoma cells using the ATP tumor chemosensitivity assay].
Kurbacher CM; Brenne U; Kurbacher JA; Mallmann P; Krebs D
Zentralbl Gynakol; 1996; 118(5):271-8. PubMed ID: 8701623
[TBL] [Abstract][Full Text] [Related]
19. [The evaluation of adenosine triphosphate bioluminescence assay for chemosensitivity testing of ovarian cancer cell line].
Shi W; Gu M; Liang L
Zhonghua Fu Chan Ke Za Zhi; 1996 Feb; 31(2):79-82. PubMed ID: 8758798
[TBL] [Abstract][Full Text] [Related]
20. Chemosensitivity and chemoresistance testing in ovarian cancer.
Cree IA
Curr Opin Obstet Gynecol; 2009 Feb; 21(1):39-43. PubMed ID: 19125002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
